Volume | 14,871 |
|
|||||
News | - | ||||||
Day High | 21.72 | Low High |
|||||
Day Low | 21.46 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Landos Biopharma Inc | LABP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
21.46 | 21.46 | 21.72 | 21.52 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
101 | 14,871 | $ 21.61 | $ 321,357 | - | 2.50 - 21.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:08:03 | 90 | $ 21.75 | USD |
Landos Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
67.51M | 3.12M | - | 0 | -21.94M | -7.04 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Landos Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LABP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 21.47 | 21.72 | 21.43 | 21.53 | 21,470 | 0.25 | 1.16% |
1 Month | 7.10 | 21.95 | 6.90 | 21.16 | 55,440 | 14.62 | 205.92% |
3 Months | 4.78 | 21.95 | 4.37 | 16.29 | 26,710 | 16.94 | 354.39% |
6 Months | 3.57 | 21.95 | 3.145 | 13.43 | 16,195 | 18.15 | 508.40% |
1 Year | 2.899 | 21.95 | 2.50 | 7.06 | 21,548 | 18.82 | 649.22% |
3 Years | 115.00 | 161.70 | 2.111 | 19.77 | 127,384 | -93.28 | -81.11% |
5 Years | 130.00 | 169.89 | 2.111 | 34.43 | 137,710 | -108.28 | -83.29% |
Landos Biopharma Description
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. The LANCE platform identifies novel therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need. |